| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.15 | 0.005 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | -0.09 | 0.005 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.006 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.006 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.09 | 0.007 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.089 | 0.007 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.077 | 0.008 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.098 | 0.008 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.008 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.21 | 0.01 |